{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T12:08:25Z","timestamp":1774094905351,"version":"3.50.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Bonn"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Primary sclerosing cholangitis (PSC) is a chronic liver disease leading to inflammation with scaring and strictures of bile ducts, which can lead to liver cirrhosis. A subtype of PSC characterized by high serum IgG4 (sIgG4) levels has been reported to be associated with poor outcomes, but the exact role and the longitudinal development of sIgG4 levels in PSC progression remains to be clarified. The aim of this study was to investigate if subsequent analysis of sIgG4 levels allows the identification of the PSC phenotype with high sIgG4.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>sIgG4 values were repeatedly analysed in a well-characterized European PSC cohort of 110 individuals. Biochemical parameters, clinical endpoints, death and liver transplantation were compared between PSC subgroups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>12.7% (<jats:italic>n<\/jats:italic>\u2009=\u200914) of PSC patients showed increased sIgG4 levels (PSC-IgG4). The values normalized in 57.1% (<jats:italic>n<\/jats:italic>\u2009=\u20098; PSC-IgG4<jats:sub>norm<\/jats:sub>) during follow-up measurements, whereas the values remained permanently elevated in 42.9% (<jats:italic>n<\/jats:italic>\u2009=\u20096; PSC-IgG4<jats:sub>const<\/jats:sub>). Serum values of AP and \u03b3GT were significantly higher in PSC-IgG4<jats:sub>const<\/jats:sub> compared to PSC-IgG4<jats:sub>norm<\/jats:sub> at final blood sampling. Furthermore, mean age at PSC diagnosis was markedly lower in PSC-IgG4<jats:sub>const<\/jats:sub> compared to PSC-IgG4<jats:sub>norm<\/jats:sub>.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This is the first study analyzing longitudinal development of sIgG4 in PSC. Our data indicate that only sequential determination of sIgG4 levels allow to accurately distinguish between the PSC phenotype with high sIgG4 and PSC with low sIgG4.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1186\/s12876-024-03343-3","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T12:06:40Z","timestamp":1722859600000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Only repeatedly elevated IgG4 levels in primary sclerosing cholangitis may distinguish a particular patient phenotype"],"prefix":"10.1186","volume":"24","author":[{"given":"Sandra","family":"Kalthoff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Wolniak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Lutz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian P.","family":"Strassburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettina","family":"Langhans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leona","family":"Dold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,5]]},"reference":[{"key":"3343_CR1","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1002\/hep.26565","volume":"58","author":"K Boonstra","year":"2013","unstructured":"Boonstra K, Weersma RK, van Erpecum KJ, et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology. 2013;58:2045\u201355.","journal-title":"Hepatology"},{"key":"3343_CR2","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1053\/j.gastro.2017.02.038","volume":"152","author":"TJ Weismuller","year":"2017","unstructured":"Weismuller TJ, Trivedi PJ, Bergquist A, et al. Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing Cholangitis. Gastroenterology. 2017;152:1975\u201384. e8.","journal-title":"Gastroenterology"},{"key":"3343_CR3","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","volume":"67","author":"TH Karlsen","year":"2017","unstructured":"Karlsen TH, Folseraas T, Thorburn D, et al. Primary sclerosing cholangitis - a comprehensive review. J Hepatol. 2017;67:1298\u2013323.","journal-title":"J Hepatol"},{"key":"3343_CR4","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1111\/j.1365-2036.2011.04658.x","volume":"33","author":"EL Culver","year":"2011","unstructured":"Culver EL, Chapman RW. Systematic review: management options for primary sclerosing cholangitis and its variant forms - IgG4-associated cholangitis and overlap with autoimmune hepatitis. Aliment Pharmacol Ther. 2011;33:1273\u201391.","journal-title":"Aliment Pharmacol Ther"},{"key":"3343_CR5","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1111\/liv.15028","volume":"41","author":"T Zhou","year":"2021","unstructured":"Zhou T, Lenzen H, Dold L, et al. Primary sclerosing cholangitis with moderately elevated serum-IgG4 - characterization and outcome of a distinct variant phenotype. Liver Int. 2021;41:2924\u201333.","journal-title":"Liver Int"},{"key":"3343_CR6","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.jhep.2022.05.011","volume":"77","author":"European Association for the Study of the Liver","year":"2022","unstructured":"European Association for the Study of the Liver. Electronic address eee, European Association for the study of the L. EASL Clinical Practice guidelines on sclerosing cholangitis. J Hepatol. 2022;77:761\u2013806.","journal-title":"J Hepatol"},{"key":"3343_CR7","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1055\/s-0043-120199","volume":"55","author":"D Gesellschaft fur Innere","year":"2017","unstructured":"Deutsche Gesellschaft fur Gastroenterologie V-uS, Gesellschaft fur Innere D, Deutsche M. [Practice guideline autoimmune liver diseases - AWMF-Reg. 021\u201327]. Z Gastroenterol. 2017;55:1135\u2013226.","journal-title":"Z Gastroenterol"},{"key":"3343_CR8","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.3748\/wjg.v26.i23.3126","volume":"26","author":"CD Manganis","year":"2020","unstructured":"Manganis CD, Chapman RW, Culver EL. Review of primary sclerosing cholangitis with increased IgG4 levels. World J Gastroenterol. 2020;26:3126\u201344.","journal-title":"World J Gastroenterol"},{"key":"3343_CR9","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1111\/j.1572-0241.2006.00772.x","volume":"101","author":"FD Mendes","year":"2006","unstructured":"Mendes FD, Jorgensen R, Keach J, et al. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol. 2006;101:2070\u20135.","journal-title":"Am J Gastroenterol"},{"key":"3343_CR10","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/MJT.0b013e3181c9dac6","volume":"18","author":"E Bjornsson","year":"2011","unstructured":"Bjornsson E, Chari S, Silveira M, et al. Primary sclerosing cholangitis associated with elevated immunoglobulin G4: clinical characteristics and response to therapy. Am J Ther. 2011;18:198\u2013205.","journal-title":"Am J Ther"},{"key":"3343_CR11","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/jhbp.432","volume":"24","author":"A Tanaka","year":"2017","unstructured":"Tanaka A, Tazuma S, Nakazawa T, et al. No negative impact of serum IgG4 levels on clinical outcome in 435 patients with primary sclerosing cholangitis from Japan. J Hepatobiliary Pancreat Sci. 2017;24:217\u201325.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"3343_CR12","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.dld.2014.06.010","volume":"46","author":"M Benito de Valle","year":"2014","unstructured":"Benito de Valle M, Muller T, Bjornsson E, et al. The impact of elevated serum IgG4 levels in patients with primary sclerosing cholangitis. Dig Liver Dis. 2014;46:903\u20138.","journal-title":"Dig Liver Dis"},{"key":"3343_CR13","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1055\/a-2060-0935","volume":"61","author":"T Kucharzik","year":"2023","unstructured":"Kucharzik T, Dignass A, Atreya R, et al. Aktualisierte S3-Leitlinie colitis ulcerosa (Version 6.1) \u2013 Februar 2023 \u2013 AWMF-Registriernummer: 021\u2009\u2013\u2009009. Z Gastroenterol. 2023;61:1046\u2013134.","journal-title":"Z Gastroenterol"},{"key":"3343_CR14","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1002\/hep.26977","volume":"59","author":"K Boonstra","year":"2014","unstructured":"Boonstra K, Culver EL, de Buy Wenniger LM, et al. Serum immunoglobulin G4 and immunoglobulin G1 for distinguishing immunoglobulin G4-associated cholangitis from primary sclerosing cholangitis. Hepatology. 2014;59:1954\u201363.","journal-title":"Hepatology"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-024-03343-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-024-03343-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-024-03343-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T12:08:36Z","timestamp":1722859716000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-024-03343-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,5]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3343"],"URL":"https:\/\/doi.org\/10.1186\/s12876-024-03343-3","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,5]]},"assertion":[{"value":"2 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of the Medical Faculty of the University of Bonn (number 128\/23-EP). Informed consent was obtained from all patients for being included in the study. The study was performed according to the Helsinki Declaration of 1975, as revised in 2008.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"248"}}